ENPP3 and renal cell adenocarcinoma: The first anti-ENPP3 mAb for the treatment of RCC was hybridoma-derived AGS-16M8F; in consideration of the high cost and long time to produce antibodies via hybridomas, a second antibody directed against ENNP3, based on the Chinese Hamster Ovary (CHO) cell line system, AGS-16C3F, was derived [58].